Royalty Pharma Plc Cl A (RPRX) |
|
52.82 1.32 (2.56%)
|
01-27 03:27 |
|
Open: |
51.56 |
Pre. Close: |
51.5 |
|
High:
|
53.15 |
Low:
|
51.53 |
|
Volume:
|
2,477,491 |
Market Cap:
|
33,025M |
|
|
|
|
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
53.155 - 53.34 |
53.34 - 53.51 |
|
Low:
|
50.999 - 51.237 |
51.237 - 51.454 |
|
Close:
|
52.44 - 52.774 |
52.774 - 53.08 |
|
Technical analysis |
as of: 2021-01-26 4:48:26 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 62.17 One year: 72.62 |
| Support: |
Support1: 47.15 Support2: 43.39 |
| Resistance: |
Resistance1: 53.23 Resistance2: 62.17 |
| Pivot: |
50.63 |
| Moving Average: |
MA(5): 51.25 MA(20): 50.23
MA(100): 43.34 MA(250): |
| MACD: |
MACD(12,26): 1.65 Signal(9): 1.71  |
| Stochastic oscillator: |
%K(14,3): 80.30 %D(3): 71.17 |
| RSI: |
RSI(14): 65.51 |
| 52-week: |
High: 56.50 Low: 34.80 Change(%): 18.7 |
| Average Vol(K): |
3-Month: 274656 10-Days: 295968 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.RPRX has closed below upper band by 7.3%. Bollinger Bands are 14.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 22 Jan 2021
Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021 - Yahoo Finance
Sun, 10 Jan 2021
Royalty Pharma Ramps Up Dividend By 13% - Nasdaq
Fri, 08 Jan 2021
Royalty Pharma Announces 13% Dividend Increase - StreetInsider.com
Fri, 08 Jan 2021
Royalty Pharma raises dividend by 13% to $0.17 per share - Seeking Alpha
Fri, 08 Jan 2021
How Does Royalty Pharma plc (RPRX) Stock Rank on Wall Street? - InvestorsObserver
Thu, 07 Jan 2021
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12 - Yahoo Finance
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: |
| Industry: |
| Shares Out. (M) |
366 |
| Shares Float (M) |
288 |
|
% Held by Insiders
|
17.50 |
|
% Held by Institutions
|
44.42 |
|
Shares Short (K)
|
13,300 |
|
Shares Short P. Month (K)
|
10,610 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
110.79 |
|
Operating Margin
|
130.16 |
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
16.0 |
|
Gross Profit (p.s.)
|
7.734 |
|
Sales Per Share
|
5.493 |
|
EBITDA (p.s.)
|
7.215 |
|
Qtrly Earnings Growth
|
-28.90 |
|
Operating Cash Flow (M)
|
1,950 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
9.61 |
|
Price to Cash Flow
|
9.91 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
0.680 |
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2021-03-14 |
|
Ex-Dividend Date
|
2020-11-18 |
|
7 Binary Options
|
|
Your Ad Here
|
|
